$10.79
-0.32-2.93%
Dern. MÀJ: Oct 23, 3:45 PM
Monte Rosa Therapeutics (GLUE) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.34 | $-0.36 | $-0.39 | $-0.37 |
| Actual | $-0.43 | $-0.45 | $-0.55 | $-0.33 |
| Surprise | -26.5% | -25.0% | -41.0% | +10.8% |
| Revenue | ||||
| Estimate | $15.4M | $13.4M | $13.4M | $7.5M |
| Actual | $9.0M | $4.2M | $2.8M | $12.8M |
| Surprise | -41.9% | -68.7% | -79.3% | +69.5% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.18 | $-0.34 | $-0.38 | $-0.39 |
| Revenue | ||||
| Consensus | $36.2M | $24.3M | — | — |
| Trimestre Fiscal | Date de Déclaration | BPA Réel | BPA Estimé | Surprendre % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $-0.43 | $-0.34 | -26.5 % |
| Q1 | May 7, 2026 | $-0.45 | $-0.36 | -25.0 % |
| Q4 | Mar 17, 2026 | $-0.55 | $-0.39 | -41.0 % |
| Q3 | Nov 6, 2025 | $-0.33 | $-0.37 | 10.8 % |
| Trimestre Fiscal | Date de Déclaration | Revenu Réel | Revenu Estimé | Surprendre % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $8.97M | $15.45M | -41.9 % |
| Q1 | May 7, 2026 | $4.21M | $13.45M | -68.7 % |
| Q4 | Mar 17, 2026 | $2.78M | $13.41M | -79.3 % |
| Q3 | Nov 6, 2025 | $12.77M | $7.53M | 69.5 % |